Alpha 2.0
Login Register
» Articles » PMID: 29438360

An RNAi-based Screen Reveals PLK1, CDK1 and NDC80 As Potential Therapeutic Targets in Malignant Pleural Mesothelioma

Overview
Journal Br J Cancer
Specialty Oncology
Date 2018 Feb 14
PMID 29438360
Citations 5
Authors
A Linton
Y Y Cheng
K Griggs
L Schedlich
M B Kirschner
S Gattani
S Srikaran
S Chuan-Hao Kao
B C McCaughan
S Klebe
N van Zandwijk
G Reid
Affiliations
Soon will be listed here.
Abstract

This corrects the article DOI: 10.1038/bjc.2017.85.

Citing Articles

as a potential pan-cancer diagnostic, prognostic, and immunological biomarker.

Tao L, Xu X, Fang Z, Christopoulos P, Cortinovis D, Lu Y Transl Cancer Res. 2024; 13(3):1533-1553.

PMID: 38617518 PMC: 11009796. DOI: 10.21037/tcr-23-2016.

Development of an interfering peptide M1-20 with potent anti-cancer effects by targeting FOXM1.

Bu H, Lan X, Cheng H, Pei C, Ouyang M, Chen Y Cell Death Dis. 2023; 14(8):533.

PMID: 37598210 PMC: 10439915. DOI: 10.1038/s41419-023-06056-9.

shRNA targeting PLK1 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells.

Zhou Y, Wu C, Liu B, Zhu J, Zhong Y, Yuan Y Transl Cancer Res. 2022; 9(9):5350-5359.

PMID: 35117900 PMC: 8798612. DOI: 10.21037/tcr-20-811.

Identification of as a candidate marker in cutaneous squamous cell carcinoma by integrated bioinformatics analysis.

Qin S, Yang Y, Zhang H, Zheng X, Li H, Wen J Transl Cancer Res. 2022; 10(1):469-478.

PMID: 35116276 PMC: 8797450. DOI: 10.21037/tcr-20-2945.

Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC).

Wijnen R, Pecoraro C, Carbone D, Fiuji H, Avan A, Peters G Cancers (Basel). 2021; 13(17).

PMID: 34503199 PMC: 8430873. DOI: 10.3390/cancers13174389.